Bromodomain and extraterminal (BET) protein inhibition of IgG/IgE production in murine B cells is counter‐balanced by a strong Th2 bias

OBJECTIVES: Inhibitors of bromodomain and extra terminal domain (BET) proteins are a new and growing class of anti‐cancer drugs, which decrease oncogene expression by targeting superenhancers. Antibody production is another physiological process relying on superenhancers, and it remains to be clarif...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalloul, Zeinab, Best, Marie, Chenuet, Pauline, Dalloul, Iman, Le Noir, Sandrine, Togbé, Dieudonnée, Gador, Mylène, Ryffel, Bernhard, FJ Quesniaux, Valerie, El Makhour, Yolla, Boyer, François, Aldigier, Jean‐Claude, Cook‐Moreau, Jeanne, Fazilleau, Nicolas, Cogné, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164936/
https://www.ncbi.nlm.nih.gov/pubmed/34136216
http://dx.doi.org/10.1002/cti2.1280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164936/
https://www.ncbi.nlm.nih.gov/pubmed/34136216
http://dx.doi.org/10.1002/cti2.1280

Ejemplares similares